BioLineRx Ltd.

Regulatory Filings • Aug 17, 2015

_________ false

C003������� �� ��� ��"�2PublicBIOLINE RX LTD9253Corporation no: 513398750Stock Exchange/Market: NASDAQ CM2271381HaMa'ayan 2 , Modi'in 7177871 , , IsraelTel: 08-6429100 , Fax: 08-6429101E.mail address: info@BioLineRx.comReported via MAGNA: 17/08/2015              Time of broadcast: 13:50 13:45:41

Company site:		www.biolinerx.com

Reference: 2015-02-098208

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000 The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on	BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment

6-K_BL8040_170815_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity:
Date of revision of form structure: 03/06/2015
- - -
Name of the Signatory: : Kotler Norman Harold , Position of Signatory in the reporting corporation: General Counsel & Company Secretary , Name of Employer Company: .
Hartum Telephone: 02-5489100 , Facsimile: 02-5489101 , E-mail: normank@biolinerx.com 1